A 28-year-old woman with moderate persistent asthma has been on inhaled salbutamol as needed for 6 months. She now presents with symptoms occurring 3–4 times per week and nocturnal awakening twice weekly. On examination, peak expiratory flow (PEF) is 65% of predicted. She has no oral candidiasis, hoarseness, or systemic side effects. Which inhaled corticosteroid regimen is most appropriate, and what is the rationale?

Explanation

## Stepped Asthma Management & ICS Selection **Key Point:** Moderate persistent asthma (symptoms 3–4 times/week, nocturnal awakening ≥2 times/month, PEF 60–80% predicted) requires step-up to low-dose inhaled corticosteroid (ICS) as controller therapy, combined with SABA as reliever [cite:GINA 2023]. ### Rationale for Low-Dose ICS **High-Yield:** Low-dose ICS (e.g., beclomethasone 100–200 µg/day, fluticasone 88–176 µg/day) is the gold standard first-line controller for persistent asthma because it: - Provides rapid anti-inflammatory effect - Reduces exacerbation frequency and nocturnal symptoms - Has excellent safety profile at low doses with minimal systemic absorption - Is cost-effective and widely available **Clinical Pearl:** The patient has no signs of local adverse effects (candidiasis, dysphonia), confirming good inhaler technique and tolerability. Low-dose ICS does not require high-dose escalation unless symptoms persist after 4–6 weeks of adherent therapy. ### ICS Potency & Dosing Hierarchy | ICS Agent | Low Dose (µg/day) | Medium Dose (µg/day) | High Dose (µg/day) | | --- | --- | --- | --- | | Beclomethasone | 100–200 | 200–400 | >400 | | Fluticasone propionate | 88–176 | 176–440 | >440 | | Budesonide | 180–360 | 360–720 | >720 | | Ciclesonide | 80–160 | 160–320 | >320 | | Mometasone | 110–220 | 220–440 | >440 | **Key Point:** Beclomethasone 100 µg twice daily (200 µg/day total) is a standard low-dose ICS regimen suitable for this patient's severity. ## Why Other Options Are Suboptimal **Warning:** High-dose ICS (fluticasone 500 µg twice daily = 1000 µg/day) is inappropriate for moderate persistent asthma; it is reserved for severe asthma or inadequate response to medium-dose ICS after 4–6 weeks. Escalating to high dose prematurely increases risk of local (oral candidiasis, dysphonia) and systemic adverse effects (HPA axis suppression, bone loss with long-term use) without evidence-based justification. **Tip:** Once-daily dosing (ciclesonide, mometasone) offers compliance advantage but is not superior to twice-daily low-dose ICS in efficacy. Ciclesonide is a pro-drug requiring hepatic esterase activation in the lung, making it useful in patients with candidiasis risk, but is not first-line for initial step-up.